Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21367749.
- Also identified by DOI 10.1158/1078-0432.CCR-11-0211.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.
Medical subject headings
- Anilides
- Hedgehog Proteins
- Neoplasms
- Pyridines
- Signal Transduction